Tearsheet
Investment Highlights Market Valuation Price Chart About ILMN Interactive Breakdown Better Bets vs. ILMN Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Illumina (ILMN)

Market Price (10/14/2025): $95.04 | Market Cap: $14.9 Bil
Sector: Health Care | Industry: Life Sciences Tools & Services

Illumina (ILMN)

Market Price (10/14/2025): $95.04
Market Cap: $14.9 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.4%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.0%, FCF Yield is 6.9%		 Weak multi-year price returns
2Y Excs Rtn is -83%, 3Y Excs Rtn is -132%		 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.3%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.0%, Rev Chg QQuarterly Revenue Change % is -4.8%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 19%		  
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 27%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 24%		  
3 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28%		  
4 Low stock price volatility
Vol 12M is 43%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.4%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.0%, FCF Yield is 6.9%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 19%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 27%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 24%
3 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28%
4 Low stock price volatility
Vol 12M is 43%
5 Weak multi-year price returns
2Y Excs Rtn is -83%, 3Y Excs Rtn is -132%
6 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.3%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.0%, Rev Chg QQuarterly Revenue Change % is -4.8%

Market Valuation & Key Metrics

ILMNS&P 500
REVENUE GROWTHVERY POOR
Rev LTM ($ Bil)4.3
Rev Chg Q-4.8%6.1%
Rev Chg LTM-3.3%5.2%
Rev Chg 3Y Avg-3.0%5.3%
PROFITABILITYGOOD
Op Inc LTM ($ Bil)0.8
Op Mgn LTM19.2%18.6%
CFO LTM ($ Bil)1.2
CFO/Rev LTM26.9%20.3%
Net Inc LTM ($ Bil)1.3
Net Inc Mgn29.4%12.7%
VALUATIONLOW
P/S3.53.2
P/CFO12.915.6
P/FCF14.620.6
P/E11.923.6
STABILITYVERY GOOD
Debt/Equity0.170.21
Cash/Assets0.190.07

ILMN Stock

Factor Drivers of Stock Movement
The 26.6% change in ILMN stock from 4/14/2025 to 10/13/2025 was primarily driven by a 27.6% change in the company's P/S Multiple.

414202510132025Change
Stock Price ($)75.0695.0326.61%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)4372.004284.00-2.01%
P/S Multiple2.733.4827.58%
Shares Outstanding (Mil)159.00157.001.26%
Cumulative Contribution26.59%

LTM = Last Twelve Months as of date shown
The -34.7% change in ILMN stock from 10/13/2024 to 10/13/2025 was primarily driven by a -33.3% change in the company's P/S Multiple.

1013202410132025Change
Stock Price ($)145.5495.03-34.71%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)4429.004284.00-3.27%
P/S Multiple5.223.48-33.34%
Shares Outstanding (Mil)159.00157.001.26%
Cumulative Contribution-34.72%

LTM = Last Twelve Months as of date shown
The -50.9% change in ILMN stock from 10/14/2022 to 10/13/2025 was primarily driven by a -46.3% change in the company's P/S Multiple.

1014202210132025Change
Stock Price ($)193.7195.03-50.94%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)4692.004284.00-8.70%
P/S Multiple6.483.48-46.27%
Shares Outstanding (Mil)157.00157.000.00%
Cumulative Contribution-50.94%

LTM = Last Twelve Months as of date shown

Price Returns Compared

 202020212022202320242025Total [1]
Returns
ILMN Return12%3%-47%-31%-1%-29%-71%
Peers Return116%24%-35%14%-36%-13%10%
S&P 500 Return16%27%-19%24%23%13%103%

Monthly Win Rates [3]
ILMN Win Rate58%67%25%33%50%33% 
Peers Win Rate65%67%38%53%42%38% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
ILMN Max Drawdown-37%-6%-53%-54%-27%-47% 
Peers Max Drawdown-34%-8%-52%-21%-43%-40% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: TMO, A, BRKR, TXG, PACB. See ILMN Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/13/2025 (YTD)

Downturns Compared

Unique KeyEventILMNS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-82.3%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven465.6%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-37.7%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven60.4%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven61 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-29.5%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven41.7%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven301 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-57.8%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven137.2%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven623 days1480 days


How Low Can It Go?

Illumina's stock fell -82.3% during the 2022 Inflation Shock from a high on 8/16/2021. A -82.3% loss requires a 465.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Illumina (ILMN)

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Better Bets than Illumina (ILMN)

 ILMNBetter Performance than ILMN
MetricValueIndustry (Life Sciences Tools & Services)
Rev Chg LTM-3.3%TMO (2.0%), DHR (1.9%), A (4.5%), IQV (3.6%), MTD (3.1%)
Rev Chg 3Y Avg-3.0%TMO (0.3%), DHR (-2.6%), A (0.8%), IQV (3.6%), MTD (0.1%)
Op Mgn LTM19.2%A (21.3%), MTD (28.4%), WAT (27.7%), MEDP (21.4%), QGEN (25.6%)
CFO/Rev LTM26.9%MEDP (27.5%), QGEN (33.1%), IRMD (35.0%), SMLR (29.0%)
FCF/Rev LTM23.9%MEDP (26.0%), QGEN (24.3%), INMD (25.9%)
Total Yield8.4%INMD (18.5%), SMLR (12.0%), FONR (8.8%), PAVM (719.6%)
 ILMNBetter Performance than ILMN
MetricValueAll Other Sectors
Rev Chg LTM-3.3%NVDA (71.6%), MSFT (14.9%), AAPL (6.0%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg-3.0%NVDA (92.0%), MSFT (12.5%), AAPL (1.8%), GOOGL (10.2%), AMZN (11.3%)
Op Mgn LTM19.2%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM26.9%NVDA (46.6%), MSFT (48.3%), GOOGL (36.0%), META (56.4%), AVGO (42.4%)
FCF/Rev LTM23.9%NVDA (43.6%), MSFT (25.4%), META (30.7%), AVGO (41.6%), V (56.8%)
Total Yield8.4%XOM (9.9%), BABA (37.8%), CVX (9.7%), WFC (10.1%), TM (2226.4%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Illumina Earnings Notes  
2ILMN Drops 11% in a Week, But Does IQV Offer Better Fundamentals?Counter-Intuitive Comparisons 
3Illumina vs IQVIA: Which Is A Better Investment?Counter-Intuitive Comparisons 
4How Does Illumina Stock Stack Up Against Its Peers?Peer Comparison 
5Better Bet Than ILMN Stock: Pay Less Than Illumina To Get More From AA, PTCT   
6Better Bet Than ILMN Stock: Pay Less Than Illumina To Get More From PTCT   
7ILMN Dip Buy Analysis  
8Illumina Total Shareholder Return (TSR): 0.0% in 2024 and -28.5% 3-yr compounded annual returns (below peer average)  
9Illumina (ILMN) Operating Cash Flow ComparisonFinancials 
10Illumina (ILMN) Net Income ComparisonFinancials 
11ARTICLES  
12ILMN’s 11% Decline in a Week Brings Valuations Into Focus – Is IQV a Better Deal? September 26th, 2025
13What’s Happening With Illumina Stock? July 11th, 2024
14Up Nearly 15% In A Week Will Illumina Stock Continue To See Higher Levels? June 7th, 2024
15Will Illumina Stock Rebound After A 65% Decline In The Ongoing Inflation Shock? July 6th, 2023
16Is Illumina Stock A Better Pick Over TMO? May 24th, 2023
Title
0DASHBOARDS
1ILMN’s 11% Decline in a Week Brings Valuations Into Focus – Is IQV a Better Deal?
2What’s Happening With Illumina Stock?
3Up Nearly 15% In A Week Will Illumina Stock Continue To See Higher Levels?
4Will Illumina Stock Rebound After A 65% Decline In The Ongoing Inflation Shock?
5Is Illumina Stock A Better Pick Over TMO?
6ARTICLES
7Illumina Earnings Notes
8ILMN Drops 11% in a Week, But Does IQV Offer Better Fundamentals?
9Illumina vs IQVIA: Which Is A Better Investment?
10How Does Illumina Stock Stack Up Against Its Peers?
11Better Bet Than ILMN Stock: Pay Less Than Illumina To Get More From AA, PTCT 
12Better Bet Than ILMN Stock: Pay Less Than Illumina To Get More From PTCT 
13ILMN Dip Buy Analysis
14Illumina Total Shareholder Return (TSR): 0.0% in 2024 and -28.5% 3-yr compounded annual returns (below peer average)
15Illumina (ILMN) Operating Cash Flow Comparison
16Illumina (ILMN) Net Income Comparison

Trade Ideas

Select past trade ideas related to ILMN and Life Sciences Tools & Services.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		-0.8%-0.8%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		0.4%0.4%0.0%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		1.4%1.4%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		10.0%10.0%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-8.0%-8.0%-8.0%
ILMN_2292020_Monopoly_xInd_xCD_Getting_Cheaper02292020ILMNIlluminaMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		33.2%65.4%-21.3%
ILMN_7312019_Monopoly_xInd_xCD_Getting_Cheaper07312019ILMNIlluminaMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		4.6%27.9%-30.1%
ILMN_12312016_Monopoly_xInd_xCD_Getting_Cheaper12312016ILMNIlluminaMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		35.5%70.6%0.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		-0.8%-0.8%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		0.4%0.4%0.0%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		1.4%1.4%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		10.0%10.0%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-8.0%-8.0%-8.0%
ILMN_2292020_Monopoly_xInd_xCD_Getting_Cheaper02292020ILMNIlluminaMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		33.2%65.4%-21.3%
ILMN_7312019_Monopoly_xInd_xCD_Getting_Cheaper07312019ILMNIlluminaMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		4.6%27.9%-30.1%
ILMN_12312016_Monopoly_xInd_xCD_Getting_Cheaper12312016ILMNIlluminaMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		35.5%70.6%0.0%

See Trefis Trade Ideas for more.

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1UAMYUnited States Antimony106.6%844.1%
2BITFBitfarms55.8%261.7%
3ASPIASP Isotopes48.5%194.0%
4USARUSA Rare Earth47.0%129698.7%
5UUUUEnergy Fuels40.6%363.4%
6TMCTMC The Metals38.5%854.5%
7SESSES AI37.9%53.0%
8GLUEMonte Rosa Therapeutics35.8%49.9%
9APGEApogee Therapeutics35.5%19.1%
10METCRamaco Resources34.7%418.5%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1VGVenture Global-35.2% 
2BNBrookfield-34.2%17.5%
3BNTBrookfield Wealth Solutions-34.1%17.5%
4BBBYBed Bath & Beyond-28.6% 
5HELEHelen Of Troy-25.9%-67.4%
6PENGPenguin Solutions-23.8%16.3%
7USNAUsana Health Sciences-22.8%-42.8%
8TASKTaskUs-22.4%-21.8%
9NFENew Fortress Energy-21.8%-87.4%
10OPENOpendoor Technologies-21.7%354.4%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1297.9%389.0%
2QUREuniQure276.2%251.2%
3UAMYUnited States Antimony238.9%844.1%
4LACLithium Americas194.8%183.8%
5RGTIRigetti Computing187.6%259.8%
6USARUSA Rare Earth175.1%129698.7%
7SESSES AI168.0%53.0%
8PLUGPlug Power156.6%83.1%
9CLPTClearPoint Neuro150.4%70.8%
10BITFBitfarms141.7%261.7%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1ANGXAngel Studios-49.7% 
2REXREX American Resources-47.9%52.0%
3VGVenture Global-33.4% 
4USNAUsana Health Sciences-32.7%-42.8%
5FLYFirefly Aerospace-31.7% 
6LDIloanDepot-31.4%43.6%
7TIPTTiptree-29.9%-13.6%
8GOSSGossamer Bio-29.5%169.7%
9PGYPagaya Technologies-29.5%201.1%
10IDTIDT-29.4%-1.3%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1UAMYUnited States Antimony106.6%844.1%
2BITFBitfarms55.8%261.7%
3ASPIASP Isotopes48.5%194.0%
4USARUSA Rare Earth47.0%129698.7%
5UUUUEnergy Fuels40.6%363.4%
6TMCTMC The Metals38.5%854.5%
7SESSES AI37.9%53.0%
8GLUEMonte Rosa Therapeutics35.8%49.9%
9APGEApogee Therapeutics35.5%19.1%
10METCRamaco Resources34.7%418.5%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1VGVenture Global-35.2% 
2BNBrookfield-34.2%17.5%
3BNTBrookfield Wealth Solutions-34.1%17.5%
4BBBYBed Bath & Beyond-28.6% 
5HELEHelen Of Troy-25.9%-67.4%
6PENGPenguin Solutions-23.8%16.3%
7USNAUsana Health Sciences-22.8%-42.8%
8TASKTaskUs-22.4%-21.8%
9NFENew Fortress Energy-21.8%-87.4%
10OPENOpendoor Technologies-21.7%354.4%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Illumina

Financials

ILMNTMOABRKRTXGPACBMedian
NameIllumina Thermo F.Agilent .Bruker 10x Geno.Pacific . 
Mkt Price95.03524.58138.2336.2311.601.6265.63
Mkt Cap14.9198.339.35.51.40.510.2
Rev LTM4,28443,2116,7883,4436441563,863
Op Inc LTM8247,8601,444329-150-604576
FCF LTM1,0246,1701,0884957-158540
FCF 3Y Avg3866,6621,308139-32-231263
CFO LTM1,1547,5781,49516667-150660
CFO 3Y Avg6288,2061,66226016-221444

Growth & Margins

ILMNTMOABRKRTXGPACBMedian
NameIllumina Thermo F.Agilent .Bruker 10x Geno.Pacific . 
Rev Chg LTM-3.3%2.0%4.5%10.4%2.0%-17.3%2.0%
Rev Chg 3Y Avg-3.0%0.3%0.8%11.6%9.1%5.5%3.2%
Rev Chg Q-4.8%3.0%10.1%-0.4%12.9%10.4%6.6%
QoQ Delta Rev Chg LTM-1.2%0.7%2.4%-0.1%3.2%2.5%1.6%
Op Mgn LTM19.2%18.2%21.3%9.5%-23.3%-387.0%13.9%
Op Mgn 3Y Avg6.7%17.4%21.5%13.7%-28.4%-255.3%10.2%
QoQ Delta Op Mgn LTM-0.6%-0.1%-0.1%-1.3%5.7%34.3%-0.1%
CFO/Rev LTM26.9%17.5%22.0%4.8%10.4%-95.8%14.0%
CFO/Rev 3Y Avg14.5%19.1%24.6%8.7%2.4%-135.8%11.6%
FCF/Rev LTM23.9%14.3%16.0%1.4%8.8%-101.3%11.6%
FCF/Rev 3Y Avg9.0%15.5%19.4%4.7%-5.8%-142.6%6.9%

Valuation

ILMNTMOABRKRTXGPACBMedian
NameIllumina Thermo F.Agilent .Bruker 10x Geno.Pacific . 
Mkt Cap14.9198.339.35.51.40.510.2
P/S3.54.65.81.62.23.13.3
P/EBIT9.923.626.028.5-18.1-0.916.8
P/E11.930.132.269.0-17.0-0.921.0
P/CFO12.926.226.333.121.4-3.323.8
Total Yield8.4%3.3%3.8%2.0%-5.9%-108.2%2.7%
Dividend Yield0.0%0.0%0.7%0.6%0.0%0.0%0.0%
FCF Yield 3Y Avg2.7%3.6%3.7%1.5%0.2%-40.2%2.1%
D/E0.20.20.10.40.11.40.2
Net D/E0.10.10.00.4-0.30.80.1

Returns

ILMNTMOABRKRTXGPACBMedian
NameIllumina Thermo F.Agilent .Bruker 10x Geno.Pacific . 
1M Rtn-0.1%9.4%12.4%17.4%-8.2%38.5%10.9%
3M Rtn-3.6%23.4%15.3%-16.0%-7.0%11.0%3.7%
6M Rtn26.6%17.0%32.0%-9.1%40.2%22.7%24.7%
12M Rtn-34.7%-11.8%-3.1%-43.6%-28.7%-18.2%-23.4%
3Y Rtn-50.9%5.2%12.4%-33.3%-54.7%-73.4%-42.1%
1M Excs Rtn-1.2%8.3%11.3%16.3%-9.3%37.4%9.8%
3M Excs Rtn-8.8%19.0%16.1%-20.1%-11.7%5.9%-1.4%
6M Excs Rtn3.0%-4.1%11.1%-30.3%20.7%-5.0%-0.6%
12M Excs Rtn-47.0%-27.0%-18.7%-58.6%-59.2%-14.3%-37.0%
3Y Excs Rtn-131.8%-79.8%-70.8%-114.2%-140.7%-154.1%-123.0%

Comparison Analyses

Financials

$ Mil | FY: 12/292025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/29/20253/30/202512/29/20249/29/20246/30/20243/31/202412/31/202310/1/20237/2/20234/2/20231/1/202310/2/2022
Filing Date8/1/20255/9/20252/12/202511/6/20248/7/20245/3/20242/16/202411/13/20238/10/20235/5/20232/17/202311/4/2022
Key Financials Quarterly            
Total Revenue1,0591,0411,1041,0801,1121,0761,1221,1191,1761,0871,0831,115
Ebitda399276283826-1,85117-40-6553849-53-3,563
Operating Income214164193253249-111-15266-88-64-106246
Net Income235131187705-1,988-126-175-754-2343-139-3,816
EPS1.490.831.174.43-12.48-0.79-1.11-4.77-1.480.02-0.89-24.26
Key Financials TTM            
Total Revenue TTM4,2844,3374,3724,3904,4294,4934,5044,4654,4614,4474,5834,699
Ebitda TTM1,784-466-725-1,048-2,529-640-608-621-3,529-4,104-3,916-3,675
Operating Income TTM82485958423952-285-238-192-12106354501
Net Income TTM1,258-965-1,222-1,584-3,043-1,289-1,160-1,124-4,186-4,487-4,404-4,153
Growth Rates Quarterly            
Total Revenue Growth-4.8%-3.3%-1.6%-3.5%-5.4%-1.0%3.6%0.4%1.2%-11.1%-9.7%0.6%
EBITDA Growth121.6%1523.5%807.5%226.1%-4971.1%-65.3%24.5%81.6%107.1%-79.3%-128.2%-814.0%
Operating Income Growth-14.1%247.7%227.0%283.3%383.0%-73.4%-43.4%-73.2%-393.3%-134.8%-358.5%145.1%
Net Income Growth111.8%204.0%206.9%193.5%-749.6%-4300.0%-25.9%80.2%56.3%-96.5%-224.1%-1303.8%
Margins Quarterly            
EBITDA Margin37.7%26.5%25.6%76.5%-166.5%1.6%-3.6%-58.5%3.2%4.5%-4.9%-319.6%
Operating Income Margin20.2%15.8%17.5%23.4%22.4%-10.3%-13.5%5.9%-7.5%-5.9%-9.8%22.1%
Net Income Margin22.2%12.6%16.9%65.3%-178.8%-11.7%-15.6%-67.4%-19.9%0.3%-12.8%-342.2%
Cash & Debt            
Total Cash1,1551,2371,2209399941,1081,0549331,5591,5182,0371,041
Total Debt2,5982,6072,6222,6742,9212,2762,2622,2723,0483,0623,5552,566
Net Debt / (Cash)1,4431,3701,4021,7351,9271,1681,2081,3391,4891,5441,5181,525
Cash Flows Quarterly            
FCF from Operations234240364316807722413910510147-52
Cash Flows TTM            
FCF from Operations TTM1,1541,000837697520545478401210230392527
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases3702001799-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC45.6%34.5%55.1%57.1%51.7%-13.6%-19.1%7.7%-10.5%-7.7%-10.9%30.2%
Return on Invested Capital (ROIC) TTM            
ROIC TTM51.5%62.7%41.7%13.8%2.7%-8.8%-7.5%-5.8%-0.4%3.1%11.0%15.4%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Core Illumina4,4384,5534,5193,2393,543
GRAIL935512  
Eliminations-26-24-5 -1
Helix    1
Total4,5054,5844,5263,2393,543


Operating Income by Segment
$ Mil20242023202220212020
Core Illumina5524818085801,008
Eliminations  0 -24
GRAIL  -931  
Helix    1
Total552481-123580985


Assets by Segment
$ Mil20242023202220212020
Core Illumina   7,5857,316
Total   7,5857,316


Price Behavior

ILMN Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta3.332.442.391.141.091.23
Up Beta5.282.371.040.930.851.17
Down Beta0.853.954.260.991.121.21
Up Capture169%132%200%183%104%100%
Bmk +ve Days13233574144420
Stock +ve Days9203065119354
Down Capture527%297%293%153%130%108%
Bmk -ve Days8192952107330
Stock -ve Days12223360131395

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date9302025
Short Interest: Shares Quantity6,607,099
Short Interest: % Change Since 9152025-10.0%
Average Daily Volume1,758,768
Days-to-Cover Short Interest3.76
Basic Shares Quantity157,000,000
Short % of Basic Shares4.2%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/31/2025-7.8%-7.0%-2.7%
5/8/2025-4.8%1.7%6.8%
1/14/2025-5.4%-2.0%-28.2%
11/4/20241.0%-1.3%-7.2%
8/6/20244.1%2.9%11.5%
5/2/2024-4.9%-10.2%-16.6%
2/8/2024-3.8%1.9%-3.0%
11/9/2023-8.0%-11.0%10.0%
...
SUMMARY STATS   
# Positive678
# Negative181716
Median Positive2.5%3.8%7.7%
Median Negative-6.2%-8.1%-8.7%
Max Positive7.9%13.3%24.9%
Max Negative-14.6%-25.5%-28.2%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025801202510-Q 6/29/2025
3312025509202510-Q 3/30/2025
12312024212202510-K 12/29/2024
93020241106202410-Q 9/29/2024
6302024807202410-Q 6/30/2024
3312024503202410-Q 3/31/2024
12312023216202410-K 12/31/2023
93020231113202310-Q 10/1/2023
6302023810202310-Q 7/2/2023
3312023505202310-Q 4/2/2023
12312022217202310-K 1/1/2023
93020221104202210-Q 10/2/2022
6302022811202210-Q 7/3/2022
3312022505202210-Q 4/3/2022
12312021218202210-K 1/2/2022
93020211105202110-Q 10/3/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Dhingra AnkurSVP, Chief Financial Officer5142025Buy81.216,100495,3812,022,616Form
1Thaysen JacobChief Executive Officer5142025Buy79.701,20095,6405,757,528Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.